Lineage Cell Therapeutics Inc (AMEX: LCTX) kicked off on Tuesday, up 1.35% from the previous trading day, before settling in for the closing price of $0.60. Over the past 52 weeks, LCTX has traded in a range of $0.50-$1.61.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 119.78% over the last five years. While this was happening, its average annual earnings per share was recorded 6.94%. With a float of $218.96 million, this company’s outstanding shares have now reached $220.42 million.
The firm has a total of 75 workers. Let’s measure their productivity. In terms of profitability, gross margin is 90.99%, operating margin of -260.7%, and the pretax margin is -229.91%.
Lineage Cell Therapeutics Inc (LCTX) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Lineage Cell Therapeutics Inc is 0.66%, while institutional ownership is 43.28%. The most recent insider transaction that took place on Nov 26 ’24, was worth 8,850. In this transaction Chief Financial Officer of this company bought 15,000 shares at a rate of $0.59, taking the stock ownership to the 25,500 shares. Before that another transaction happened on Nov 26 ’24, when Company’s General Counsel bought 15,000 for $0.60, making the entire transaction worth $9,000. This insider now owns 22,184 shares in total.
Lineage Cell Therapeutics Inc (LCTX) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.04 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 6.94% per share during the next fiscal year.
Lineage Cell Therapeutics Inc (AMEX: LCTX) Trading Performance Indicators
Take a look at Lineage Cell Therapeutics Inc’s (LCTX) current performance indicators. Last quarter, stock had a quick ratio of 2.48. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 15.35.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.11, a number that is poised to hit -0.03 in the next quarter and is forecasted to reach -0.11 in one year’s time.
Technical Analysis of Lineage Cell Therapeutics Inc (LCTX)
Analysing the last 5-days average volume posted by the [Lineage Cell Therapeutics Inc, LCTX], we can find that recorded value of 1.67 million was better than the volume posted last year of 1.02 million. As of the previous 9 days, the stock’s Stochastic %D was 77.50%. Additionally, its Average True Range was 0.06.
During the past 100 days, Lineage Cell Therapeutics Inc’s (LCTX) raw stochastic average was set at 16.52%, which indicates a significant decrease from 45.32% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 180.20% in the past 14 days, which was higher than the 88.15% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.7941, while its 200-day Moving Average is $0.9828. Now, the first resistance to watch is $0.6198. This is followed by the second major resistance level at $0.6322. The third major resistance level sits at $0.6494. If the price goes on to break the first support level at $0.5902, it is likely to go to the next support level at $0.5730. Now, if the price goes above the second support level, the third support stands at $0.5606.
Lineage Cell Therapeutics Inc (AMEX: LCTX) Key Stats
The company with the Market Capitalisation of 133.88 million has total of 188,837K Shares Outstanding. Its annual sales at the moment are 8,950 K in contrast with the sum of -21,490 K annual income. Company’s last quarter sales were recorded 3,780 K and last quarter income was -3,030 K.
